MaxCyte, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
MaxCyte, Inc. (MXCT) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $448.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-13
- MaxCyte, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $227.00K, a 15.23% increase year-over-year.
- MaxCyte, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $221.00K, a 22.10% increase year-over-year.
- MaxCyte, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $215.00K, a 76.23% increase year-over-year.
- MaxCyte, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $209.00K, a 74.17% increase year-over-year.
- MaxCyte, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $802.00K, a 68.84% increase from fiscal 2024.
- MaxCyte, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $475.00K, a 20.25% increase from fiscal 2023.
- MaxCyte, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $395.00K, a 48.50% decline from fiscal 2022.
- MaxCyte, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $767.00K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $227.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $448.00K 10-Q · filed 2026-08-13 | $663.00K derived: sum of 3 quarters · filed 2026-08-13 | $872.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $221.00K 10-Q · filed 2026-05-13 | $436.00K derived: sum of 2 quarters · filed 2026-05-13 | $645.00K derived: sum of 3 quarters · filed 2026-05-13 | $842.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $215.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $424.00K derived: sum of 2 quarters · filed 2026-03-25 | $621.00K derived: sum of 3 quarters · filed 2026-08-13 | $802.00K 10-K · filed 2026-03-25 |
| 2025-09-30 | $209.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $406.00K derived: sum of 2 quarters · filed 2026-08-13 | $587.00K 10-Q · filed 2025-11-13 | $709.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $197.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $378.00K 10-Q · filed 2026-08-13 | $500.00K derived: sum of 3 quarters · filed 2026-08-13 | $620.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $181.00K 10-Q · filed 2026-05-13 | $303.00K derived: sum of 2 quarters · filed 2026-05-13 | $423.00K derived: sum of 3 quarters · filed 2026-05-13 | $540.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $122.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $242.00K derived: sum of 2 quarters · filed 2026-03-25 | $359.00K derived: sum of 3 quarters · filed 2026-03-25 | $475.00K 10-K · filed 2026-03-25 |
| 2024-09-30 | $120.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $237.00K derived: sum of 2 quarters · filed 2025-11-13 | $353.00K 10-Q · filed 2025-11-13 | $462.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $117.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $233.00K 10-Q · filed 2025-08-06 | $342.00K derived: sum of 3 quarters · filed 2025-08-06 | $438.00K derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $116.00K 10-Q · filed 2025-05-08 | $225.00K derived: sum of 2 quarters · filed 2025-05-08 | $321.00K derived: sum of 3 quarters · filed 2025-05-08 | $415.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $109.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $205.00K derived: sum of 2 quarters · filed 2025-03-11 | $299.00K derived: sum of 3 quarters · filed 2025-03-11 | $395.00K 10-K · filed 2025-03-11 |
| 2023-09-30 | $96.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $190.00K derived: sum of 2 quarters · filed 2024-11-06 | $286.00K 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $94.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $190.00K 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | $96.00K 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | $767.00K 10-K · filed 2024-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |